1. Home
  2. OIS vs EVO Comparison

OIS vs EVO Comparison

Compare OIS & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oil States International Inc.

OIS

Oil States International Inc.

SELL

Current Price

$8.31

Market Cap

485.0M

Sector

Industrials

ML Signal

SELL

Logo Evotec SE

EVO

Evotec SE

SELL

Current Price

$1.59

Market Cap

568.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
OIS
EVO
Founded
1995
1993
Country
United States
Germany
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
485.0M
568.6M
IPO Year
2000
2007

Fundamental Metrics

Financial Performance
Metric
OIS
EVO
Price
$8.31
$1.59
Analyst Decision
Buy
Buy
Analyst Count
4
3
Target Price
★ $11.25
$4.48
AVG Volume (30 Days)
★ 997.0K
65.9K
Earning Date
10-30-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.17
N/A
Revenue
★ $1,088,133,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$9.11
$18.90
P/E Ratio
$50.35
★ N/A
Revenue Growth
★ 62.26
N/A
52 Week Low
$5.83
$1.33
52 Week High
$14.50
$3.87

Technical Indicators

Market Signals
Indicator
OIS
EVO
Relative Strength Index (RSI) 47.00 47.71
Support Level $8.02 $1.50
Resistance Level $8.87 $1.61
Average True Range (ATR) 0.41 0.06
MACD -0.04 0.00
Stochastic Oscillator 19.15 25.00

Price Performance

Historical Comparison
OIS
EVO

About OIS Oil States International Inc.

Oil States International Inc is a provider of manufactured products and services to customers in the energy, military and industrial sectors. The company operates through three business segments - Offshore Manufactured Products, Completion and Production Services and Downhole Technologies. Its customers include many national oil and natural gas companies, and independent oil and natural gas companies, offshore drilling companies and other oilfield service, defense and industrial companies.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: